FAM150A和FAM150B是间变性淋巴瘤激酶的激活配体。

FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase.

作者信息

Guan Jikui, Umapathy Ganesh, Yamazaki Yasuo, Wolfstetter Georg, Mendoza Patricia, Pfeifer Kathrin, Mohammed Ateequrrahman, Hugosson Fredrik, Zhang Hongbing, Hsu Amy W, Halenbeck Robert, Hallberg Bengt, Palmer Ruth H

机构信息

Department of Medical Biochemistry and Cell Biology, Instititute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Five Prime Therapeutics Inc., South San Francisco, United States.

出版信息

Elife. 2015 Sep 29;4:e09811. doi: 10.7554/eLife.09811.

Aberrant activation of anaplastic lymphoma kinase (ALK) has been described in a range of human cancers, including non-small cell lung cancer and neuroblastoma (Hallberg and Palmer, 2013). Vertebrate ALK has been considered to be an orphan receptor and the identity of the ALK ligand(s) is a critical issue. Here we show that FAM150A and FAM150B are potent ligands for human ALK that bind to the extracellular domain of ALK and in addition to activation of wild-type ALK are able to drive 'superactivation' of activated ALK mutants from neuroblastoma. In conclusion, our data show that ALK is robustly activated by the FAM150A/B ligands and provide an opportunity to develop ALK-targeted therapies in situations where ALK is overexpressed/activated or mutated in the context of the full length receptor.